Screened 2026-09-11 · the tape above runs as of 21:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Sabra Health Care REIT, Inc. holds its Accumulation at $20.52. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-09-11
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$20.52
Valuation
78.92 trailing · 25.33 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.64
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
46.42%
Below 33%
Interest-bearing debt is 46.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.19%
Below 33%
Cash held in interest-bearing accounts and securities is 1.2% of assets, under the one-third limit.
Pass
Receivables
3.33%
Below 49%
Money owed to the company is 3.3% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. The price runs 12.4% above the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Healthcare Property Owner Priced Beyond Its Value
Picture a landlord collecting rent from nursing homes and clinics across America. The cash keeps flowing, yet the price tag on those properties sits well above what the numbers justify. Sabra trades at $20.11 against our fair value of $16.95, leaving no margin of safety and an opportunity rating of none. Forward earnings sit at 27.1 times while return on equity manages only 6 percent, a thin reward for the capital tied up in bricks and leases.
Revenue growth of 22 percent looks lively on paper and the ethical screen clears without issue. Profit margins hold at 19 percent. Still the valuation leaves little room for the modest returns the business actually delivers. Fourteen analysts may lean buy with a median target of $22, but that does not change the gap between price and what the underlying real estate cash flows support.
Healthcare property values can swing with government reimbursement rates and occupancy shifts. A cyclical downturn in senior care demand would hit earnings faster than the current multiple suggests. Low returns on equity already flag limited pricing power. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SBRA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it buy, with a mean price target of $23.
2026-08-12Markup · changed$20.91+11.6%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it buy, with a mean price target of $23.
2026-07-18Accumulation$18.73+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (13 analysts) rates it buy, with a mean price target of $23.
2026-07-03Accumulation$18.73+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$18.73Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
